Bank of America’s Envoy Medical Warrant COCHW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.57K Hold
23,833
﹤0.01% 5685
2025
Q4
$906 Sell
23,833
-1
-0% ﹤0.01% 6478
2025
Q3
$882 Hold
23,834
﹤0.01% 7508
2025
Q2
$834 Hold
23,834
﹤0.01% 7568
2025
Q1
$787 Hold
23,834
﹤0.01% 7460
2024
Q4
$1.1K Hold
23,834
﹤0.01% 7275
2024
Q3
$1.55K Hold
23,834
﹤0.01% 7167
2024
Q2
$1.19K Hold
23,834
﹤0.01% 7206
2024
Q1
$2.53K Hold
23,834
﹤0.01% 7095
2023
Q4
$477 Buy
23,834
+1
+0% ﹤0.01% 7288
2023
Q3
$2.12K Hold
23,833
﹤0.01% 7132
2023
Q2
$1.02K Hold
23,833
﹤0.01% 7241
2023
Q1
$739 Hold
23,833
﹤0.01% 7333
2022
Q4
$906 Sell
23,833
-333
-1% -$16 ﹤0.01% 7361
2022
Q3
$2K Hold
24,166
﹤0.01% 7560
2022
Q2
$2K Hold
24,166
﹤0.01% 7768
2022
Q1
$6K Sell
24,166
-42,022
-63% -$18.1K ﹤0.01% 7854
2021
Q4
$52K Hold
66,188
﹤0.01% 7197
2021
Q3
$42K Hold
66,188
﹤0.01% 7127
2021
Q2
$61K Buy
+66,188
New +$47.2K ﹤0.01% 6739

Other funds holding COCHW

Bank of America's COCHW Position: Q1 2026 in Review

Bank of America held its Envoy Medical Warrant (COCHW) position steady in Q1 2026 at 23,833 shares worth $1.57K. The position accounts for ﹤0.01% of the portfolio, ranked #5685.

Bank of America first reported a position in COCHW in Q2 2021 and has held it in 20 quarters since. The position peaked at $61K in Q2 2021. 34 funds tracked by Wall St. Rank hold COCHW as of Q1 2026.

  • Bank of America held 23,833 shares of Envoy Medical Warrant worth $1.57K as of Q1 2026.
  • Bank of America left its Envoy Medical Warrant share count unchanged in Q1 2026.
  • Envoy Medical Warrant made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5685 holding.
  • Bank of America first reported a position in Envoy Medical Warrant in Q2 2021 and has held it in 20 quarters since.
  • Bank of America's Envoy Medical Warrant position peaked at $61K in Q2 2021.
  • 34 funds tracked by Wall St. Rank held Envoy Medical Warrant as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.